Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitae Obtains Proof-Of-Mechanism Data For BACE Inhibition In Alzheimer’s

This article was originally published in The Pink Sheet Daily

Executive Summary

Two programs partnered with Germany’s Boehringer Ingelheim are advancing, with a type 2 diabetes program moving into Phase II while a BACE inhibitor for Alzheimer’s offers demonstrates strong ability to decrease amyloid beta levels in the brain. Vitae went public in September, netting $48.4 million from its IPO.

You may also be interested in...



Vitae May Look To Public Markets After Nearly A Decade Of Self-Sustained Growth

Alzheimer’s collaboration with Boehringer Ingelheim heads into the clinic, triggering a $14 million milestone payment to Vitae. But as the discovery specialist focuses more on autoimmune conditions and less on primary care, it also may want to increase involvement in clinical development and even commercialization of its discoveries.

In Alzheimer’s, There’s A Lot Of Room Under The Radar

At the Alzheimer’s Association International Conference in July, a number of companies reported findings alongside headliners Lilly, Merck and AstraZeneca.

Autoimmune RORγt Program May Portend Change Of Direction For Vitae

The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel